The European Medicines Agency (EMA) has concluded that a COVID-19 booster vaccination with the Moderna vaccine may be considered for people aged 18 years and above.
EMA announced in Amsterdam that Moderna’s vaccine Spikevax could be given six to eight months after the second jab.
According to experts, the third shot has increased antibody levels in adults that suffered a decline in their vaccination protection.
The EMA experts reviewed data from studies conducted by the manufacturer.
According to the EMA’s recommendation, a booster vaccination consists of half the dose used for the primary vaccination schedule.
The risk of possible side effects is the same as with the second dose.
EMA stressed that the implementation of a booster vaccination campaign was a decision made by national authorities.
EMA had previously approved booster vaccination with Pfizer/BioNTech.